| abstract |
FIELD: chemistry.SUBSTANCE: invention relates to a compound of formula I, which is an inhibitor of lysine-specific demethylase 1 (LSD1), its racemate, R-isomer, S-isomer, pharmaceutical salt and mixtures thereof, methods for their preparation, pharmaceutical compositions based on them, their use for treatment and a method of treating a malignant tumor disease associated with the activity of LSD1, an inhibitor of LSD1. According to the general formula I, A is selected from the group consisting of a substituted or unsubstituted 6-12 membered aromatic ring, a substituted or unsubstituted 5-10 membered aromatic heterocyclic ring containing 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, wherein each substituted aromatic ring or substituted aromatic heterocyclic ring contains from 1 to 2 substituents, each R1is either absent, or selected from the group consisting of unsubstituted phenyl, hydrogen, substituted or unsubstituted C1-C6 alkyl, -SO2Ra, -NHC(O)Ra, -C(O)O (CH2)mRa, -C(O)ORa, -C(O)Ra, -C(O)NRaRb, -C(S)NRaRb, -NRcRd, a substituted or unsubstituted amino group, a substituted or unsubstituted sulfonamide, substituted or unsubstituted 6-12 membered arylC1-C3alkyl and unsubstituted 5-6 membered heteroarylC1-C3alkyl with one nitrogen or sulfur atom as a heteroatom, where m is an integer from 1 to 2. Each Ra is hydrogen, unsubstituted phenyl, substituted or unsubstituted C3-C7 cycloalkyl, a substituted or unsubstituted 6-membered heterocyclic group with one nitrogen atom as heteroatom, substituted or unsubstituted C3-C7heterocycloC1-alkyl with one nitrogen atom as heteroatom, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkenyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted phenylC1-C2 alkyl, or substituted or unsubstituted 5-9 membered heteroarylC1-C2 alkyl with one heteroatom selected from nitrogen, sulfur and oxygen, Rb is hydrogen or C1-C3 alkyl, or when attached to the same atom, Ra and Rb together form a 5 or 6 membered heterocycloalkyl ring; Rc and Rd are each independently selected from hydrogen, unsubstituted C1-C3 straight or branched chain alkyl, unsubstituted benzyl; R3 is C1-C4 alkyl, acyl, —C(O)CF3, or hydrogen; W is - (CH2) 1-2- or -CH(Re) -, where Re is CN or C1-alkyl; Y is N, C, or absent; X is N or C; Z is O or (CH2) q, where q = 0-1, and when q = 0, Z is a bond; n is 0, provided that when Z is O, then Y is N and X is C.EFFECT: malignant tumour treatment.18 cl, 7 tbl, 136 ex |